Promoter holding
64.27%
SI
Sanofi India Limited - Due diligence report
A 360° intelligence report on Sanofi: trust score, financial health, credit view, compliance, directors, growth and distress signals - gener…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Sanofi — 360° Intelligence Report
Generated from MCA filings & public records69/100
Trust Score
Moderate
Sanofi is assessed as Moderate with a Trust Score of 69/100. Sanofi is an active public limited indian non-government company incorporated in 1956, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 21 Jul 2026 from the latest processed filings. Sanofi India Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
69/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
60/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
30/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 25 open (170.72 cr) · 16 satisfied (40.81 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 9 | 48.0 cr |
| Icici Limited | 11 | 48.0 cr |
| Hdfc Limited | 2 | 48.0 cr |
| Grindlays Bank | 2 | 48.0 cr |
| The First National City | 2 | 48.0 cr |
| American Express Bank Ltd. | 2 | 48.0 cr |
Compliance Score: 60/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Dec 2024).
- Litigation present in 4 court forum(s).
- Delayed payments to MSME suppliers disclosed (10 disclosure(s)).
- 17 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 30/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| DEEPAK ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RENEE VISWONATH AMONKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VAIBHAV VINAYAK KARANDIKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RODOLFO HROSZ | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rachid Ayari | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| USHA THORAT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Eric Yves Mansion | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAHUL BHATNAGAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ADITYA NARAYAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rachid Ayari | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mahadev Keshav Gawade | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 11 directors on the board.
- DEEPAK ARORA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 7 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Hoechst Gmbh (holding Company)
Subsidiaries
1
Group entities
1
Capital events
-
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Sanofi Consumer Healthcare India Limited | Subsidiary Company | 74.00% |
| Hoechst Gmbh (holding Company) | Holding Company | 74.00% |
| Sanofi Sa(ultimate Holding Company ) | Holding Company | 74.00% |
Key managerial personnel: DEEPAK ARORA (Managing Director) · RENEE VISWONATH AMONKAR (Whole-time director) · Rachid Ayari (Whole-time director) · Mahadev Keshav Gawade (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 70
Growth signals & trust indicators
Operating for 70+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Profit declined two years in a row.
6 director exits within 2 years.
25 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 14.92 Lakh.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence66/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 25 open charge(s) of 170.72 cr already registered.
- Compliance gaps should be priced into terms.
Investor view63/100
Mixed indicators
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events27 Oct 2025
Director appointed
DEEPAK ARORA (Managing Director)
Director ceased
DEEPAK ARORA
26 Oct 2025
Director ceased
Rachid Ayari
11 Aug 2025
Director appointed
Mahadev Keshav Gawade (Whole-time director)
Director ceased
RENEE VISWONATH AMONKAR
Director ceased
Mahadev Keshav Gawade
15 May 2025
Last AGM held
Annual general meeting
31 Dec 2024
Latest balance sheet
Filed with ROC
15 Nov 2024
Director ceased
RADHIKA KARTIK SHAH
07 Aug 2024
Director ceased
Eric Yves Mansion
03 Jun 2024
Director appointed
Eric Yves Mansion (Director)
12 Jan 2024
Director appointed
Rachid Ayari (Cfo)
01 Dec 2023
Director appointed
Rachid Ayari (Whole-time director)
22 Nov 2023
Charge satisfied
Icici Limited
11 Oct 2023
Charge satisfied
Grindlays Bank
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
11 active director(s) / partner(s); review board churn before relying on management continuity.
17 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Jll | L24240MH1992PLC128651 | Mumbai, Maharashtra, India |
| Bayer | U99999GJ1990PTC049322 | Vapi, Gujarat, India |
| Huber | U24220GJ1991PTC016598 | Vapi, Gujarat, India |
| Adama Agricultural Solutions | U24110TG1998PTC072870 | Medchal Malkajgiri District, Telangana, India |
| Lanxess India Private Limited | U24119MH2004PTC158377 | Thane, Maharashtra, India |
| Hetero Drugs | U24230TG1993PLC015582 | Hyderabad, Telangana, India |
| Sanmargroup | U24100TN1991PLC020589 | Chennai, Tamil Nadu, India |
| Apl Healthcare Limited | U24239TG2006PLC052053 | Hyderabad, Telangana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sanofi before audits and certifications: compliance score 60/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sanofi: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Sanofi - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 69/100, distress signals and MSME payment-delay disclosures - know whether Sanofi pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Sanofi - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sanofi an active company?
Sanofi has MCA status “Active” with a compliance score of 60/100 (Moderate).
Is Sanofi financially healthy?
Sanofi has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.
Should I do business with Sanofi?
Its overall Trust Score is 69/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sanofi?
The ultimate holding entity is Hoechst Gmbh (holding Company). 11 active director(s) are on record.
Does Sanofi have loans or charges against its assets?
25 open charge(s) are registered against its assets, and 16 earlier charge(s) stand satisfied.
Is Sanofi up to date with its ROC filings?
Balance sheet slightly behind (Dec 2024). Overall compliance score: 60/100 (Moderate).
Is it risky to lend to Sanofi?
Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
